Portfolio of Cancer Immunotherapy Stocks

Here are 23 cancer immunotherapy stocks.


23 Cancer Immunotherapy Stocks

Stock Returns & Price Chart

Symbol

Recent Prices &
Annualized Return

AmgenAMGN
AstraZenecaAZN
BeiGene Ltd.BGNE
Bellicum PharmaceuticalsBLCM
bluebird bioBLUE
Bristol-Myers SquibbBMY
CelgeneCELG
Celldex TherapeuticsCLDX
CellectisCLLS
CelyadCYAD
Clovis OncologyCLVS
Compugen Ltd.CGEN
CurisCRIS
CytomX TherapeuticsCTMX
Five Prime TherapeuticsFPRX
Gilead SciencesGILD
Incyte CorporationINCY
MerckMRK
NantKwestNK
Nektar TherapeuticsNKTR
NovartisNVS
PfizerPFE
ZIOPHARM OncologyZIOP
Price data from Quandl as of most recent close.



To inspect the performance of the Cancer Immunotherapy Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.

The 14 stocks included in the portfolio computations are: AMGN, AZN, BMY, CELG, CLDX, CGEN, CRIS, GILD, INCY, MRK, NKTR, NVS, PFE and ZIOP. The current value of the portfolio assumes that $714.29 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. The 9 stocks excluded from the portfolio computations because of insufficient price data are: BGNE, BLCM, BLUE, CLLS, CYAD, CLVS, CTMX, FPRX and NK.

The current value of a $10,000 investment is $47,226. The percent return is 372.26%. The annualized return is 16.79%.




Return Summary for Cancer Immunotherapy Stocks
Start DateMay-29-2009
Start Investment$10,000.00
End DateMay-24-2019
Current Value of Investment$47,225.64
Total Return372.26%
Annualized Return16.79%
Min DateMay-29-2009
Min Price$10,000.00
Max DateNov-30-2015
Max Price$60,097.20
# Values121
Number Returns7,260
Number Profitable Returns6,159
Percent Profitable Returns84.83%
Number Unprofitable Returns1,101
Percent Unprofitable Returns15.17%
Profitable to Unprofitable Returns Ratio5.59



NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.


Related Portfolios

Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks

Portfolio of Biotech Stocks

Portfolio of Immune Checkpoint Inhibitor Stocks